Cash buyers are snapping up unique tech at bargain prices — long freshly acquired and licensed names

Verdict: A promising deal-driven thesis, but no entry has fired — stay on the watch list

The thesis has real narrative force: three strategic deals landed within days — Schneider's $23B bid for PTC at a decade-low multiple (per MarketWatch), Roche's up-to-$1.27B Parkinson's licensing of Alector (per Reuters), and Qualcomm's pop on Huawei patent news (per the Bloomberg movers piece, October 5, 2026) — and PTC's fiscal Q4 showed 42.7% year-over-year revenue growth with a 48.5% operating margin, the profile of an asset a strategic buyer deems cheap. The strongest counterpoint is that the most recent quarter deteriorated sharply at two of the three names: Qualcomm's June-quarter net income fell 72.8% sequentially to $2.0B and free cash flow fell 74.2% to $495M, while PTC's net income dropped 79.9% to $118.8M — and insider filings show net open-market selling at both ALEC (about -$158,600 across four holders, period ended June 30, 2026) and QCOM (about -$11.3M across seven holders, provisional for the period ended September 30, 2026). Critically, this is a rules-not-triggered watch list: over 185 daily bars in the last nine months the entry conditions never fired, and PTC's RSI of 89.2 is already past the 75 exit line while QCOM sits $1.45 below its 21-day EMA with RSI at 44.1 and ADX at 14.7. The verdict is wait — act only when a specific, observable entry condition prints, starting with ALEC's low touching $2.22 and closing above it. A confirmed second filing showing continued insider selling at ALEC or QCOM would flip the view against the setup entirely.

Trade now: three setups, none fully live — here is the exact checklist

None of the three entries has fired, and the setup is explicitly a watch-list right now: the rules were evaluated on real daily bars but did not open a trade, so the plan today is to wait for specific, observable conditions rather than chase. **ALEC (last close $2.185)** is closest. Price is above the 21-day EMA ($2.01), RSI (14) is 66.5 — inside the required 50–70 band — and ADX (14) is 22.4, above the 18 floor. The one unmet condition is the support retest: the day's low must touch the first support level at $2.22 (about 1.6% above the close) while the close holds above it. If that prints, the take-profit sits at the announcement-high resistance of $2.20 and the structural stop is a close below the second support at $2.10, with a hard -2.35% stop and +4.70% take-profit also armed. Note the resistance target sits slightly below the current price, so the fixed 4.7% target likely governs the trade's reward; risk is capped at roughly 2.3%, giving an effective reward-to-risk near 2-to-1. **PTC ($192.5)** is too hot to buy. RSI (14) is 89.2 — the strategy needs it between 50 and 70 — and the price is 32% above the 21-day EMA ($144.89), far from the first support at $157.97 where a retest entry would form. The overbought RSI exit level (75) is already breached, so any hypothetical position here would be flagged for exit immediately. Waiting means a pullback toward the $146.72–$157.97 support zone with RSI cooling back under 70. **QCOM ($182.21)** fails three of four momentum conditions: price is $1.45 below the 21-day EMA of $183.67, RSI (14) is 44.1 (needs above 50), and ADX (14) is 14.7 (needs above 18). A same-day reclaim of the EMA plus RSI back over 50 and ADX above 18, combined with a low that tags first support at $180 while closing above it, would be the trigger. One scope note: no robust parameter setup was established for this strategy because the frozen rule set could not be fully evaluated on the data, so the published thresholds are used as-is. Evidence here is rules-not-triggered, not a trust deficit — the entry is simply far from current market conditions, as the stress review notes.

Strategic Bids Confirm the Re-Rating Premium

The idea's core claim — that unique-technology companies re-rate sharply and quickly when a strategic buyer arrives — is backed by three concrete, same-day catalysts: PTC rallied on the Schneider deal, Alector soared after Roche licensed its Parkinson's therapy for up to $1.27 billion (per Reuters), and Qualcomm popped on the Huawei chip patent licensing news, all grouped in the Bloomberg movers piece published October 5, 2026. The MarketWatch article adds the valuation hook: the $23 billion software deal was struck at a decade-low multiple, which is precisely the 'strategic owners see value the market doesn't' premise of the thesis. The fundamentals behind the targets give the trade a real anchor rather than pure narrative. PTC's fiscal fourth quarter (ended September 2025) shows 42.7% year-over-year revenue growth, a 48.5% operating margin, a 38.9% net margin, and $100.5 million in quarterly free cash flow — the 88th percentile for growth and the 99th percentile for free cash flow among software peers. That is the profile of a cash-generative asset trading where a strategic buyer thinks it is cheap. Qualcomm's latest reported quarter (ended June 2026) is still solidly profitable: $9.9 billion in revenue, $2.0 billion in net income, a 20.1% net margin, and a 16.3% operating margin. Alector is unprofitable but improving — its Q2 2026 free cash burn narrowed from $49.9 million to $34.2 million and revenue grew 217% quarter-over-quarter to $3.3 million — so the strategic Roche bid arrives while the downside is shrinking rather than widening. Important context on the setup itself: the rules were evaluated on real daily bars over the last nine months (185 bars) and did not open an entry, so this is a watch-list setup, not an active signal — the entry conditions (a deal pop followed by a support retest with trend and momentum intact) have not occurred in the evaluated window. The thesis is therefore awaiting its next catalyst, and with three strategic deals (Schneider, Roche, Huawei) landing within days of each other, the environment for new candidates looks active rather than dormant.

Three Targets, Three Warning Signs

The most recent sequential numbers cut hard against the 'bargain valuation' framing. Qualcomm's net income fell 72.8% quarter-over-quarter to $2.0 billion in the quarter ended June 2026, free cash flow fell 74.2% to $495 million, and operating margin contracted 5.4 points to 16.3%. PTC's net income fell 79.9% sequentially to $118.8 million in the same period, its operating margin dropped 10.5 points to 27.7%, and revenue fell 22.5% to $600.0 million. If the thesis rests on buyers paying decade-low prices for cash-generative assets, cash generation deteriorated sharply…

Scores

• Conviction score breakdown: 46
• Thesis support: 70
• Trade readiness: 25
• Risk quality: 50
• Trigger proximity: 45
• Fundamentals trend: 40

Watch items

• ALEC — Daily low vs first support
• ALEC — Close vs second support
• QCOM — Price vs EMA (21)
• QCOM — RSI (14)
• QCOM — ADX (14)
• QCOM — Insider net open-market selling
• PTC — RSI (14)
• PTC — Price vs first support
• PTC — Debt-to-equity
• ALEC — Insider net open-market selling